514 related articles for article (PubMed ID: 33923802)
1. Antiplatelet Therapy Combined with Anastrozole Induces Features of Partial EMT in Breast Cancer Cells and Fails to Mitigate Breast-Cancer Induced Hypercoagulation.
Xulu KR; Augustine TN
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33923802
[TBL] [Abstract][Full Text] [Related]
2. Breast cancer cell-induced platelet activation is compounded by tamoxifen and anastrozole in vitro.
Pather K; Dix-Peek T; Duarte R; Chetty N; Augustine TN
Thromb Res; 2019 May; 177():51-58. PubMed ID: 30851629
[TBL] [Abstract][Full Text] [Related]
3. Breast Tumor Cells Evade the Cytotoxic Action of Anastrozole, Aspirin, and Clopidogrel Cocktail.
Arnachellen D; Xulu KR; Pillay K; Augustine TN
Microsc Microanal; 2023 Jun; 29(3):1205-1219. PubMed ID: 37749673
[TBL] [Abstract][Full Text] [Related]
4. Combined Anastrozole and Antiplatelet Therapy Treatment Differentially Promotes Breast Cancer Cell Survival.
Xulu K; Duarte R; Augustine T
Microsc Microanal; 2020 Jun; 26(3):497-508. PubMed ID: 32241309
[TBL] [Abstract][Full Text] [Related]
5. Modelling the procoagulatory effect of Anastrozole relative to ERα and ERβ expression in breast cancer cells.
Pather K; Augustine TN
J Thromb Thrombolysis; 2022 Oct; 54(3):401-410. PubMed ID: 35932382
[TBL] [Abstract][Full Text] [Related]
6. Atopaxar. A novel player in antiplatelet therapy?
Wurster T; May AE
Hamostaseologie; 2012; 32(3):228-33. PubMed ID: 22859265
[TBL] [Abstract][Full Text] [Related]
7. Edoxaban Plus Aspirin vs Dual Antiplatelet Therapy in Endovascular Treatment of Patients With Peripheral Artery Disease: Results of the ePAD Trial.
Moll F; Baumgartner I; Jaff M; Nwachuku C; Tangelder M; Ansel G; Adams G; Zeller T; Rundback J; Grosso M; Lin M; Mercur MF; Minar E;
J Endovasc Ther; 2018 Apr; 25(2):158-168. PubMed ID: 29552984
[TBL] [Abstract][Full Text] [Related]
8. Emerging antiplatelet therapy for coronary artery disease and acute coronary syndrome.
Packard KA; Campbell JA; Knezevich JT; Davis EM
Pharmacotherapy; 2012 Mar; 32(3):244-73. PubMed ID: 22392457
[TBL] [Abstract][Full Text] [Related]
9. Aspirin, clopidogrel and prasugrel monotherapy in patients with type 2 diabetes mellitus: a double-blind randomised controlled trial of the effects on thrombotic markers and microRNA levels.
Parker WAE; Schulte C; Barwari T; Phoenix F; Pearson SM; Mayr M; Grant PJ; Storey RF; Ajjan RA
Cardiovasc Diabetol; 2020 Jan; 19(1):3. PubMed ID: 31910903
[TBL] [Abstract][Full Text] [Related]
10. Emerging oral antiplatelet therapies for acute coronary syndromes.
Pollack CV
Hosp Pract (1995); 2010 Nov; 38(4):29-37. PubMed ID: 21068524
[TBL] [Abstract][Full Text] [Related]
11. The pharmacodynamics of antiplatelet compounds in thrombosis treatment.
Jayakumar T; Yang CH; Geraldine P; Yen TL; Sheu JR
Expert Opin Drug Metab Toxicol; 2016 Jun; 12(6):615-32. PubMed ID: 27055051
[TBL] [Abstract][Full Text] [Related]
12. Prevention of arterial thrombosis by edoxaban, an oral factor Xa inhibitor in rats: monotherapy and in combination with antiplatelet agents.
Honda Y; Kamisato C; Morishima Y
Eur J Pharmacol; 2016 Sep; 786():246-252. PubMed ID: 27288116
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Antiplatelet Therapies for Prevention of Patent Foramen Ovale-Associated Stroke.
Kasner SE; Randall B; Andersen G; Iversen HK; Roine RO; Sjostrand C; Rhodes JF; Søndergaard L;
J Stroke Cerebrovasc Dis; 2020 Apr; 29(4):104632. PubMed ID: 32037269
[TBL] [Abstract][Full Text] [Related]
14. Randomized trial of atopaxar in the treatment of patients with coronary artery disease: the lessons from antagonizing the cellular effect of Thrombin–Coronary Artery Disease Trial.
Wiviott SD; Flather MD; O'Donoghue ML; Goto S; Fitzgerald DJ; Cura F; Aylward P; Guetta V; Dudek D; Contant CF; Angiolillo DJ; Bhatt DL;
Circulation; 2011 May; 123(17):1854-63. PubMed ID: 21502571
[TBL] [Abstract][Full Text] [Related]
15. Adverse clinical outcomes associated with double dose clopidogrel compared to the other antiplatelet regimens in patients with coronary artery disease: a systematic review and meta-analysis.
Zhuo X; Zhuo B; Ouyang S; Niu P; Xiao M
BMC Pharmacol Toxicol; 2018 Sep; 19(1):54. PubMed ID: 30176938
[TBL] [Abstract][Full Text] [Related]
16. Tamoxifen induces hypercoagulation and alterations in ERα and ERβ dependent on breast cancer sub-phenotype ex vivo.
Pather K; Augustine TN
Sci Rep; 2020 Nov; 10(1):19256. PubMed ID: 33159119
[TBL] [Abstract][Full Text] [Related]
17. Clopidogrel response variability is associated with endothelial dysfunction in coronary artery disease patients receiving dual antiplatelet therapy.
Siasos G; Oikonomou E; Zaromitidou M; Kioufis S; Kokkou E; Mourouzis K; Vlasis K; Vavuranakis M; Stone PH; Papavassiliou AG; Tousoulis D
Atherosclerosis; 2015 Sep; 242(1):102-8. PubMed ID: 26188531
[TBL] [Abstract][Full Text] [Related]
18. Switching of Hormone Therapies in Breast Cancer Women.
Medeiros LM; Stahlschmidt R; Ferracini AC; Souza CM; Juliato CRT; Mazzola PG
Rev Bras Ginecol Obstet; 2021 Mar; 43(3):185-189. PubMed ID: 33465792
[TBL] [Abstract][Full Text] [Related]
19. Different levels of blood pressure, different benefit from dual antiplatelet therapy in minor stroke or TIA patients.
Xu J; Tao Y; Li H; Gu H; Xie X; Meng X; Xu Y; Wang Y; Wang Y
Sci Rep; 2017 Jun; 7(1):3884. PubMed ID: 28634365
[TBL] [Abstract][Full Text] [Related]
20. Extended antiplatelet therapy with clopidogrel alone versus clopidogrel plus aspirin after completion of 9- to 12-month dual antiplatelet therapy for acute coronary syndrome patients with both high bleeding and ischemic risk. Rationale and design of the OPT-BIRISK double-blinded, placebo-controlled randomized trial.
Li Y; Jing Q; Wang B; Wang X; Li J; Qiao S; Chen S; Angiolillo DJ; Han Y
Am Heart J; 2020 Oct; 228():1-7. PubMed ID: 32739652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
